Teva, Axsome

Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute with peer Teva
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.
Axsome settles Auvelity patent litigation with Teva
Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a proposed generic version of Auvelity. Read more here.
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The settlement resolves all patent litigation related to Axsome’s Auvelity (dextromethorphan HBr – bupropion HCl) product.
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.
Axsome Therapeutics Shares Rise After Agreement with Teva Pharmaceuticals Ends Litigation
Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after Sept. 30, 2039, if no pediatric exclusivity is granted.
Axsome Therapeutics stock rises on patent litigation settlement
Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized the value of the innovation behind AUVELITY. With the settlement, Axsome can continue advancing its pipeline of new medicines without the overhang of patent disputes.
Why Axsome Therapeutics Stock Is Skyrocketing Today
Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
FiercePharma10d
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Truist maintains Buy on Axsome shares, reiterates $190 target
Truist Securities maintained a positive stance on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy rating and a $190.00 ...
FDA approves Symbravo for acute treatment of migraine in adults
The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...
Axsome Therapeutics price target raised to $150 from $110 at Leerink
Leerink raised the firm’s price target on Axsome Therapeutics (AXSM) to $150 from $110 and keeps an Outperform rating on the shares. The ...
BofA raises Axsome stock target on extended Auvelity exclusivity
BofA Securities analyst Jason Gerberry increased the price target for Axsome Therapeutics (NASDAQ:AXSM) shares to $167 from the previous $143, while reiterating a Buy rating on the stock. This aligns ...
Mizuho Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target increased by equities researchers at Mizuho from ...